Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Return on Sales (2016 - 2025)

Anaptysbio filings provide 10 years of Return on Sales readings, the most recent being 0.84% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 171.0% year-over-year to 0.84%, compared with a TTM value of 0.0% through Dec 2025, up 250.0%, and an annual FY2025 reading of 0.0%, up 159.0% over the prior year.
  • Return on Sales hit 0.84% in Q4 2025 for Anaptysbio, up from 0.3% in the prior quarter.
  • The five-year high for Return on Sales was 13.48% in Q4 2023, with the low at 32.38% in Q1 2022.
  • Median Return on Sales over the past 5 years was 3.22% (2024), compared with a mean of 8.33%.
  • The sharpest move saw Return on Sales plummeted -3131bps in 2021, then surged 2632bps in 2022.
  • Year by year, Return on Sales stood at 30.75% in 2021, then surged by 86bps to 4.43% in 2022, then skyrocketed by 404bps to 13.48% in 2023, then plummeted by -107bps to 0.88% in 2024, then skyrocketed by 195bps to 0.84% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.84%, 0.3%, and 1.74% for Q4 2025, Q3 2025, and Q2 2025 respectively.